These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

908 related articles for article (PubMed ID: 15824338)

  • 1. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
    Roxburgh RH; Seaman SR; Masterman T; Hensiek AE; Sawcer SJ; Vukusic S; Achiti I; Confavreux C; Coustans M; le Page E; Edan G; McDonnell GV; Hawkins S; Trojano M; Liguori M; Cocco E; Marrosu MG; Tesser F; Leone MA; Weber A; Zipp F; Miterski B; Epplen JT; Oturai A; Sørensen PS; Celius EG; Lara NT; Montalban X; Villoslada P; Silva AM; Marta M; Leite I; Dubois B; Rubio J; Butzkueven H; Kilpatrick T; Mycko MP; Selmaj KW; Rio ME; Sá M; Salemi G; Savettieri G; Hillert J; Compston DA
    Neurology; 2005 Apr; 64(7):1144-51. PubMed ID: 15824338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
    Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
    Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multiple sclerosis severity score (MSSS) predicts disease severity over time.
    Pachner AR; Steiner I
    J Neurol Sci; 2009 Mar; 278(1-2):66-70. PubMed ID: 19138773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
    Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C
    J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis of the individual course of disease: the elements of time, heterogeneity and precision.
    Daumer M; Neuhaus A; Herbert J; Ebers G
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S50-5. PubMed ID: 20106349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylsulfatase a gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression.
    Baronica KB; Mlinac K; Ozretić D; Vladić A; Bognar SK
    Coll Antropol; 2011 Jan; 35 Suppl 1():11-6. PubMed ID: 21648305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and quality of life of multiple sclerosis in Spain.
    Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs and quality of life in multiple sclerosis in The Netherlands.
    Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
    Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs and quality of life of multiple sclerosis in Austria.
    Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in disability profile and quality of life in multiple sclerosis patients: a five-year longitudinal study using the Multiple Sclerosis Impact Profile (MSIP).
    Wynia K; van Wijlen AT; Middel B; Reijneveld SA; Meilof JF
    Mult Scler; 2012 May; 18(5):654-61. PubMed ID: 21965423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample.
    Idiman E; Uzunel F; Ozakbas S; Yozbatiran N; Oguz M; Callioglu B; Gokce N; Bahar Z
    J Neurol Sci; 2006 Jan; 240(1-2):77-80. PubMed ID: 16277993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between MRI parameters and the MS severity scale: a 12 year follow-up study.
    Minneboo A; Uitdehaag BM; Jongen P; Vrenken H; Knol Dl; van Walderveen MA; Polman CH; Castelijns JA; Barkhof F
    Mult Scler; 2009 May; 15(5):632-7. PubMed ID: 19389751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.
    Drake AS; Weinstock-Guttman B; Morrow SA; Hojnacki D; Munschauer FE; Benedict RH
    Mult Scler; 2010 Feb; 16(2):228-37. PubMed ID: 20028710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cigarette smoking and progression in multiple sclerosis.
    Koch M; van Harten A; Uyttenboogaart M; De Keyser J
    Neurology; 2007 Oct; 69(15):1515-20. PubMed ID: 17923613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and quality of life of multiple sclerosis in Italy.
    Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs and quality of life for patients with multiple sclerosis in Belgium.
    Kobelt G
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs and quality of life of multiple sclerosis in Switzerland.
    Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient reported outcomes in benign multiple sclerosis.
    Hviid LE; Healy BC; Rintell DJ; Chitnis T; Weiner HL; Glanz BI
    Mult Scler; 2011 Jul; 17(7):876-84. PubMed ID: 21372114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and quality of life of multiple sclerosis in Germany.
    Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.